Evidence map›Paper›PMID 24348215›Full record

ArticleThe Yale journal of biology and medicine2013

DNA damage tolerance and a web of connections with DNA repair at Yale.

Richard D Wood

Open access · greenAbstract read
In one paragraph

Article in The Yale journal of biology and medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Richard D WoodDepartment of Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas, and Graduate School of Biomedical Sciences at Houston, Houston, Texas.
The University of Texas MD Anderson Cancer Center · US

Funding

Recognition and processing of complex lesions by components from multiple DNAP01CA097175 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NAIRN, RODNEY S · 2004 to 2014
$15.3M
Function of REV3L in limiting oncogenesis via DNA damage toleranceR01CA132840 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WOOD, RICHARD D · 2009 to 2013
$1.6M
NCI NIH HHS CA09717NCI NIH HHS CA132840NCI NIH HHS P01 CA097175NCI NIH HHS R01 CA132840
6 · The paper itself

Abstract

This short article summarizes some of the research carried out recently by my laboratory colleagues on the function of DNA polymerase zeta (polζ) in mammalian cells. Some personal background is also described, relevant to research associations with Yale University and its continuing influence. Polζ is involved in the bypass of many DNA lesions by translesion DNA synthesis and is responsible for the majority of DNA damage-induced point mutagenesis in mammalian cells (including human cells), as well as in yeast. We also found that the absence of this enzyme leads to gross chromosomal instability in mammalian cells and increased spontaneous tumorigenesis in mice. Recently, we discovered a further unexpectedly critical role for polζ: it plays an essential role in allowing continued rapid proliferation of cells and tissues. These observations and others indicate that polζ engages frequently during DNA replication to bypass and tolerate DNA lesions or unusual DNA structures that are barriers for the normal DNA replication machinery.

Indexed as

DNA DamageDNA RepairAnimalsCell ProliferationCells, CulturedConnecticutDNADNA-Directed DNA PolymeraseGenomic InstabilityHumansMiceModels, GeneticMutagenesisResearchSaccharomyces cerevisiaeUltraviolet RaysDNADNA-Directed DNA PolymeraseDNA polymerase zetaDNA damageDNA polymerasemousepol zetaultraviolet radiation

Identifiers

PMID24348215
PMCPMC3848105
OpenAlexW1561444567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.